Navigation Links
Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2012
Date:1/25/2012

PALO ALTO, Calif., Jan. 25, 2012 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) today is reporting results for the first quarter of fiscal year 2012 with net earnings of $0.79 per diluted share, down 1 percent from the year-ago quarter. Revenues for the quarter were $625 million, up 8 percent from the year-ago period. Including $48 million in proton therapy backlog, the company ended the first quarter with a $2.5 billion backlog, up 14 percent from the end of the first quarter in fiscal 2011.  

"While we met our guidance for net earnings and revenues, this was a challenging quarter for the company in a variety of ways," said Tim Guertin, president and CEO of Varian Medical Systems.  "We experienced order push outs in our North American oncology business and X-Ray Product orders and sales were hurt by inventory adjustments by our customers in Japan. As anticipated, the gross margin was impacted by a tough year-ago comparison, product mix, and accounting for Scripps proton revenue with zero margin.  Additionally our operating margin was impacted by the dilutive effects of the Calypso acquisition."  

The company ended the first quarter with $606 million in cash and cash equivalents and $188 million of debt.

Oncology SystemsOncology Systems' first quarter revenues totaled $488 million, up 8 percent from the same period of fiscal year 2011.  First-quarter net orders were $485 million, up 6 percent, with a 22 percent increase in international markets offsetting an 11 percent decline in North America versus the comparable year-ago period."Net orders in all international regions were up in solid double digits, comprising nearly 60 percent of the net orders received by this business during the quarter," Guertin said.  "Several orders that we were aiming for in North America during the quarter were pushed out, but we fully expect that w
'/>"/>

SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 2015 Taiwan,s GNT ... in Taipei on  August 25 ... platform, a targeted drug delivery technology that uses nano-scale ... was part of a joint press conference held by ... (GNT), showcasing GNT,s latest edible gold-based food and beverage ...
(Date:9/1/2015)... 1, 2015 Sargas Pharmaceutical Adherence and ... Drug Adherence m Health applications along with 24 ... of non face-to-face monitoring of twenty minutes per ... of our apps, doctors are now well prepared ... our ONCHIT certified Physician, Pharmacy and Patient portals ...
(Date:9/1/2015)... Agena Bioscience TM today announced the establishment ... commercial and financial hub from which many biotech and life ... in mainland China . "The ... sales with almost sixty MassARRAY ® Systems installed to ... allow us to expand our reach and foster a high ...
Breaking Medicine Technology:GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Agena Bioscience Opens Office in Shanghai, China 2
... today announced positive results from a Phase 1 trial ... in vitro anti-pseudomonal activity. The results from ... well tolerated, with a clinical and laboratory safety profile ... toxicity was observed, even at the highest dose regimen ...
... 23 Each year in the United States more than ... These new cases account for 10 percent of the new ... several types of leukemia, the survival rate has not changed ... Golubieski, president of Foundation Venture Capital Group, LLC, a New ...
Cached Medicine Technology:Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity 2Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments 2
(Date:9/1/2015)... ... 01, 2015 , ... In an article published ... the country are switching from traditional dental impressions to digital impressions using CAD/CAM ... Sam Saleh of Ora Dentistry Spa, his practice has been an early pioneer ...
(Date:9/1/2015)... ... September 01, 2015 , ... ProRehab ... to announce their partnership with Apex Physical Therapy (Apex) is official ... to provide kind, compassionate, and empathetic care to local residents from their combined ...
(Date:9/1/2015)... WA (PRWEB) , ... September 01, 2015 , ... Philanthropic ... increasing awareness of societal issues and needs. Money for Good 2015, released today by ... solving it. There’s an annual potential to mobilize up to $22B in new philanthropic ...
(Date:9/1/2015)... Eagan, Minnesota (PRWEB) , ... September 01, 2015 ... ... covered health care delivery options, Blue Cross and Blue Shield of Minnesota (Blue ... starting in 2016. , Based in San Francisco, Doctor On Demand provides ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... top-five hospital by U.S. News & World Report, to provide breaking news and ... Editorial and marketing groups within OncLive, which provides oncologists resources and information?they need ...
Breaking Medicine News(10 mins):Health News:Article on CAD/CAM Dental Technology Highlights the Advantages of 21st Century Dentistry, Notes Ora Dentistry Spa 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3
... WHO: Martin Payne, Executive Vice President, Sales ... Leigh Hocker Radtke, Director, Software Product Management, SkyeTek, ... 2:00 PM - 3:00 PM EDT, ... DESCRIPTION: Medical sales processes are becoming increasingly complex,due to changes ...
... BETHLEHEM, Pa., June 24 At this year,s ... Inc. and its MIKE AND,IKE(R) Candy Brand presented ... the first in a multi-year commitment to this ... MIKE AND IKE(R) Lemonade Blends(TM) kicks off Just ...
... today announced the signing of a distribution agreement ... will enhance selling,efforts for Hill-Rom,s product The Vest(R) ... facilities within the United States., "We are ... Kim,Dennis, group vice president, Post Acute Care at ...
... Fla., June 24 Synovics,Pharmaceuticals, Inc. (OTC ... announced that its wholly owned subsidiary,ANDAPharm, LLC ... pharmaceutical,company for the manufacturing and supply of ... by ANDAPharm with this product, including an,earlier ...
... authored by a University of Queensland academic has ... key factors in the transmission of MRSA (Meticillin ... Dr Archie Clements, from the School of Population ... MRSA infections, which lead to increased inpatient hospital ...
... busy units, even basic hand-washing can get lost in ... 24 (HealthDay News) -- Overcrowding and understaffing can cause ... aureus (MRSA) in hospitals, Australian researchers report. ... Health, University of Queensland, noted that hospitals in many ...
Cached Medicine News:Health News:SkyeTek to Host Webinar Discussing RFID-Based Solution for Medical Sales Processes Automation 2Health News:MIKE AND IKE(R) Lemonade Blends(TM) Presents $100,000 to Alex's Lemonade Stand Foundation 2Health News:Hill-Rom Announces Agreement With Tri-anim to Enhance Distribution Channels for The Vest(R) System in U.S. Hospitals & Long-Term Care Facilities 2Health News:Hill-Rom Announces Agreement With Tri-anim to Enhance Distribution Channels for The Vest(R) System in U.S. Hospitals & Long-Term Care Facilities 3Health News:Hill-Rom Announces Agreement With Tri-anim to Enhance Distribution Channels for The Vest(R) System in U.S. Hospitals & Long-Term Care Facilities 4Health News:Synovics Pharmaceuticals Announces Execution of Hormonal Manufacture and Supply Contract 2Health News:Synovics Pharmaceuticals Announces Execution of Hormonal Manufacture and Supply Contract 3Health News:Synovics Pharmaceuticals Announces Execution of Hormonal Manufacture and Supply Contract 4Health News:Synovics Pharmaceuticals Announces Execution of Hormonal Manufacture and Supply Contract 5Health News:Overcrowding and understaffing in hospitals increases levels of MRSA infections 2Health News:MRSA Rates Tied to Hospital Understaffing 2
...
No. 1. 30 mm conventional blades. Thin well-rounded tips....
Open blade speculum designed for both temporal and superior approach ocular surgery. Thumb screw adjusting mechanism. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Medicine Products: